- Purple Urine Bag Syndrome
-
Lee KW, Lee YJ, Kim DH, Kim YH, Kim ME, Park YH
- KMID: 2292510
- Korean J Urol.
- 2002 Oct;43(10):902-903.
Purple urine bag syndrome (PUBS) is a rare phenomenon where the urinary catheter and bag turns purple following catheterization. The colors are formed from the substrate indoxyl sulfate (indican). PUBS... -
- CITED
-
- Close
- SHARE
-
- Close
- Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor
-
Akbar MF
- KMID: 2390929
- Transl Clin Pharmacol.
- 2017 Sep;25(3):114-116.
- doi: 10.12793/tcp.2017.25.3.114
Indoxyl sulfate, a protein-bound uremic toxin, leads to CKD (chronic kidney disease) progression and its complications through the activation of AhR (aryl hydrocarbon receptor) and RAS (renin-angiotensin system). Inhibition of... -
- CITED
-
- Close
- SHARE
-
- Close
- Paricalcitol attenuates indoxyl sulfate-induced apoptosis through the inhibition of MAPK, Akt, and NF-κB activation in HK-2 cells
-
Park JS, Choi HI, Bae EH, Ma SK, Kim SW
- KMID: 2452498
- Korean J Intern Med.
- 2019 Jan;34(1):146-155.
- doi: 10.3904/kjim.2016.298
BACKGROUND/AIMS: Indoxyl sulfate (IS) is a uremic toxin and an important causative factor in the progression of chronic kidney disease. Recently, paricalcitol (19-nor-1,25-dihydroxyvitamin D2) was shown to exhibit protective effects... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Oral Adsorbent AST-120 (Kremezin(R)) on the Progression of Chronic Kidney Disease
-
Lee YK, Moon SJ, An HR, Kim JK, Bae SC, Kim BS, Park HC, Ha SK
- KMID: 2253016
- Korean J Nephrol.
- 2010 Jul;29(4):450-457.
PURPOSE: AST-120 is known to delay progression of chronic kidney disease (CKD) when combined with other proven therapy. AST-120 is an oral adsorbent for uremic toxin, such as indoxyl sulfate... -
- CITED
-
- Close
- SHARE
-
- Close
- p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis
-
Hyun HS, Paik KH, Cho HY
- KMID: 1427932
- Korean J Pediatr.
- 2013 Apr;56(4):159-164.
- doi: 10.3345/kjp.2013.56.4.159
PURPOSE: Indoxyl sulfate and p-cresyl sulfate are important protein-bound uremic retention solutes whose levels can be partially reduced by renal replacement therapy. These solutes originate from intestinal bacterial protein fermentation... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment
-
Kim AH, Yoon S, Lee Y, Lee J, Bae E, Lee H, Kim DK, Lee S, Yu KS, Jang IJ, Cho JY
- KMID: 2429888
- J Korean Med Sci.
- 2018 Dec;33(53):e298.
- doi: 10.3346/jkms.2018.33.e298
BACKGROUND: The renal function of individuals is one of the reasons for the variations in therapeutic response to various drugs. Patients with renal impairment are often exposed to drug toxicity,... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study
-
Hwang YC, Kim SW, Hur KY, Cha BS, Kim IJ, Park TS, Baik SH, Yoon KH, Lee KW, Lee IK, Lee MK
- KMID: 2443205
- J Korean Med Sci.
- 2019 Apr;34(15):e117.
- doi: 10.3346/jkms.2019.34.e117
BACKGROUND: Removal of uremic toxins such as indoxyl sulfate by AST-120 is known to improve renal function and delay the initiation of dialysis in patients with advanced chronic kidney disease.... -
- CITED
-
- Close
- SHARE
-
- Close
- Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea
-
Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, Yoon SA, Kim S, Han SY, Park JH, Chang JH, Lim CS, Kim YS
- KMID: 2409391
- Kidney Res Clin Pract.
- 2017 Mar;36(1):68-78.
- doi: 10.23876/j.krcp.2017.36.1.68
BACKGROUND: We investigated the long-term effect of AST-120, which has been proposed as a therapeutic option against renal disease progression, in patients with advanced chronic kidney disease (CKD). METHODS: We performed... -
- CITED
-
- Close
- SHARE
-
- Close
